Tailor-made therapy of multi-resistant tuberculosis
The successful treatment of multidrug-resistant tuberculosis requires clarification in advance as to which antibiotics the pathogens are resistant to. Classic testing in the laboratory is very time-consuming and delays the start of therapy. Researchers from the Research Center Borstel, the Leibniz Lung Center, and the German Center for Infection Research (DZIF) have now prepared a catalogue of all mutations in the genome of tuberculosis bacteria and on the basis of a genome sequencing can quickly and cheaply predict which medicines are most effective for tuberculosis treatment. The results of this work were published in the professional journal Clinical Infectious Diseases.
Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly. While other typical pathogens, such as pneumococcal and pseudomonads, can already be identified by their growth in the microbiological laboratory in the first 72 hours, several weeks usually pass before tuberculosis bacteria grow in the lab. Thus it often takes one to two months before the efficacy of individual medicines can be tested.
However, these efficacy tests are essential for the effective treatment of multidrug-resistant tuberculosis (MDR-TB), which is becoming increasingly common. In these cases, the pathogen has become resistant, i.e. insensitive, to the best tuberculosis drugs, rifampicin and isoniazid. This is due to changes in the genome, so-called mutations, which almost always occur at the same points in the genome. Treatment of MDR-TB is protracted, costly and frequently associated with side effects.
For the selection of antibiotics in a combination therapy, doctors have so far depended on the results of the drug test after cultivation. “Currently, 15 drugs are available for second-line therapy, of which at least four are used in combination,” explains Prof. Christoph Lange, coordinator of the clinical study at the Research Center Borstel.
In order to accelerate the choice of the most effective antibiotics, DZIF scientists at the Research Center Borstel, led by Prof. Stefan Niemann, have created a catalogue of mutations in the genetic material of tuberculosis bacteria that permits prediction of antibiotic resistances of the bacteria against all drugs. Unlike many other bacteria, the genetic material of the tuberculosis bacteria hardly changes over time. The genome of tuberculosis bacteria carries roughly 4.4 millions of building blocks (base pairs) that store the information for about 4,000 genes.
Hans-Peter Grobbel, medical student and predoctoral DZIF fellow in Christoph Lange's team, supported by his fellow student Niklas Köhler, Professor Matthias Merker, Dr Sönke Andres and Dr Harald Hoffmans, has examined the results of antibiotic resistance predictions through overall genome analyses. Using tuberculosis bacteria from70 patients with MDR-TB treated at the Borstel Department of Medicine, researchers compared the molecular prediction of antibiotic resistance with actual cultural test results. They were contributed by Prof. Florian Maurer, Head of the National Reference Laboratory for Tuberculosis Bacteria in Borstel. The scientists also examined whether reliable combinations of drugs for the treatment of MDR-TB could be compiled based on the prediction of the bacteria’s genetic material.
“Ninety-nine per cent of all drugs in combination therapies that we have assembled based on the results of molecular predictions from the genetic material of tuberculosis bacteria are also effective according to traditional microbiological antibiotic resistance testing,” Grobbel explains. By now, the molecular methods are both cheap and fast. Ideally, patients can already receive tailored MDR-TB treatment in the first week of their tuberculosis diagnosis.
